List view / Grid view

Articles

Drug Target Review – Issue 4 2023

21 December 2023 | By

A new Drug Target Review issue is now ready to download! This issue features articles on CRISPR, personalised medicine and screening.

The future of mRNA biology and AI convergence

21 December 2023 | By

In the rapidly evolving landscape of mRNA biology and artificial intelligence (AI), Anima Biotech stands at the forefront, a unique approach that reshapes our understanding of diseases and transforms the drug discovery process. mRNA biology holds immense potential with RNAi drugs in the market and mRNA vaccines showing promise, particularly…

The first major set of genetic associations found in long COVID

13 December 2023 | By

PrecisionLife’s Dr Sayoni Das, a computational biologist who leads the research and development of bioinformatics pipelines that generate biological insights from PrecisionLife’s core technology and support drug discovery programmes, details a new study. Using combinatorial analysis, genetic variants associated with long COVID have been identified and, furthermore, it has been…

The future of lymphoma treatment

12 December 2023 | By

In the current landscape of drug discovery, lymphoma poses a significant challenge and opportunity. Researchers are fervently exploring novel therapeutic avenues, such as Antibody-Drug Conjugates (ADCs), to address the complexities of lymphoma. ARC-02, a standout candidate, demonstrates enhanced efficacy and tolerability in lymphoma treatment. While eyeing a diverse ADC pipeline,…

Women in Stem with Andrea Pfeifer

30 November 2023 | By

This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership,…

Let’s talk neuroscience with Michelle Sidor at SFN

29 November 2023 | By

Drug Target Review’s Taylor Mixides met with Dr Michelle Sidor, the Director of Neuroscience at Alchemab Therapeutics, and Dr Sifis Pediaditakis at the Society for Neuroscience event this November. This exclusive interview explores neuroscientific research and its pivotal role in steering the company toward future triumphs. Michelle highlights the dynamic…